TABLE 1.
Description of Candida isolates included in the study
| Organism(s) | No. of isolates | % of isolates | No. of isolates with indicated susceptibilitya: |
|
|---|---|---|---|---|
| S-DD/I | R | |||
| C. albicans | 29 | 27.9 | 0 | 0 |
| C. tropicalis | 27 | 25.9 | 0 | 0 |
| C. parapsilosis | 28 | 26.9 | 1 to VRC | 1 to FLC |
| C. glabrata | 8 | 7.7 | 7 to FLC, 3 to CAS | 1 to FLC |
| Non-albicans Candida | 4 | 3.8 | 0 | 1 to FLC |
| C. lusitaniae | 4 | 3.8 | 0 | 1 to FLC |
| C. pelliculosa | 2 | 1.9 | 0 | 0 |
| C. albicans + C. kruseib | 2 | 1.9 | 0 | 0 |
| Total | 104 | 100 | 9/104 | 4/104 |
a
Isolates were categorized as S-DD and R to voriconazole and fluconazole when tested according to standard protocol and susceptibility criteria as described in reference 18. VRC, voriconazole; FLC, fluconazole; CAS, caspofungin; S-DD, susceptible-dose dependent; I, intermediate susceptibility; R, resistant.
b
These isolates were categorized according to the standard susceptibilities of the most resistant of the two isolates (C. krusei in both cases).